Opinion|Videos|July 29, 2024
Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape
Advertisement
Episodes in this series
1. Please review recently presented data from the TROPION trial series investigating Dato-DXd in patients with previously treated NSCLC. Briefly outline the design and key endpoints for these studies. What are some key takeaways from these data and what implications may findings have the treatment landscape?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 10/4/2026
2
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
3
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
4
FDA Flashback: Hematologic Cancer Decisions and News From September 2026
5